Donna Cullen Greene - 03 Mar 2022 Form 4 Insider Report for NEXTGEN HEALTHCARE, INC.

Role
EVP, Human Resources
Signature
/s/Jeffrey D. Linton, Attorney-in-Fact for Donna Cullen Greene
Issuer symbol
N/A
Transactions as of
03 Mar 2022
Net transactions value
-$314,714
Form type
4
Filing time
04 Mar 2022, 18:12:54 UTC
Previous filing
28 Dec 2021
Next filing
28 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NXGN Common Stock Options Exercise $166,400 +10,000 +17% $16.64 69,460 03 Mar 2022 Direct
transaction NXGN Common Stock Options Exercise $84,668 +6,625 +9.5% $12.78 76,085 03 Mar 2022 Direct
transaction NXGN Common Stock Options Exercise $278,290 +17,000 +22% $16.37 93,085 03 Mar 2022 Direct
transaction NXGN Common Stock Options Exercise $431,400 +30,000 +32% $14.38 123,085 03 Mar 2022 Direct
transaction NXGN Common Stock Sale $1,275,471 -63,625 -52% $20.05 59,460 03 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXGN Stock Option (right to buy) Options Exercise $0 -10,000 -16% $0.000000 53,625 03 Mar 2022 Common Stock 10,000 $16.64 Direct F2
transaction NXGN Stock Option (right to buy) Options Exercise $0 -6,625 -12% $0.000000 47,000 03 Mar 2022 Common Stock 6,625 $12.78 Direct F3
transaction NXGN Stock Option (right to buy) Options Exercise $0 -17,000 -36% $0.000000 30,000 03 Mar 2022 Common Stock 17,000 $16.37 Direct F4
transaction NXGN Stock Option (right to buy) Options Exercise $0 -30,000 -100% $0.000000* 0 03 Mar 2022 Common Stock 30,000 $14.38 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $19.99. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request.
F2 Original grant of 10,000 options granted on 5/22/2015 vested in five equal, annual installments beginning 5/22/2016.
F3 Original grant of 26,500 options granted on 5/25/2016 vested in four equal, annual installments beginning 5/25/2017.
F4 Original grant of 20,000 options granted on 6/13/2017 vested in four equal, annual installments beginning 6/13/2018.
F5 Original grant of 40,000 options granted on 12/4/2017 vested in four equal, annual installments beginning 12/4/2018.